Medical Description
Antidiabetic agent belongs to Biguanide group used in treatment and prevention of type 2 diabetes mellitus and treatment of polycystic ovary syndrome.
Indication & Usage
-Prevention of type 2 diabetes mellitus: For prediabetic patients, particularly for those with BMI ≥35 kg/m2, age <60 years, and patients with prior gestational diabetes mellitus, in whom lifestyle interventions fail to improve glycemic indices: Immediate release formulations: Oral: Initial: 850 mg once daily for 1 month, then increase to 850 mg twice daily; unless GI adverse effects warrant a longer titration period. -Treatment of type 2 diabetes mellitus: A-Immediate release: 1-Initial: Oral: 500 mg once or twice daily or 850 mg once daily. 2-Dosage adjustments: Oral: The dose should be increased gradually to minimize GI adverse effects. Titrate the dose by 500 mg or 850 mg increments every 7 days (range: 5 days to 1 month). 3-Usual maintenance dosage: Oral: 1 g twice daily or 850 mg twice daily. Maximum dose: Oral: 2.55 g/day. If doses >2 g/day are needed, consider administering in 3 divided doses to minimize GI adverse effects. B-Extended release: 1-Initial: Oral: 500 mg to 1 g once daily 2-Dosage adjustments: Oral: The dose should be increased gradually to minimize GI adverse effects. Titrate the dose by 500 mg increments every 7 days (range: 7 days to 6 weeks). Maximum dose: Oral: 2 g/day. -Treatment of gestational diabetes mellitus: Immediate release: Oral: Initial: 500 mg once or twice daily; increase dosage to meet glycemic targets, typically over 1 to 2 weeks, up to a maximum of 2 to 2.5 g daily in 2 to 3 divided doses. -Polycystic ovary syndrome (PCOS): A-Treatment of oligomenorrhea due to PCOS: Immediate release: Oral: Dosage range: 1.5 to 2 g daily in 2 to 3 divided doses; to minimize GI adverse effects, it is recommended to initiate therapy with 500 mg once or twice daily and gradually increased the dose in 500 mg